HOUSTON–(BUSINESS WIRE)–IFM Investors today announced that Julio Garcia, Head of Infrastructure, North America, has advised of his intention to retire after more than 18 years with the firm. Garcia will step down from his executive responsibilities following a transition period. He will continue to contribute to IFM through his appointment to the Investment Committee, where his experience and expertise will remain an important asset to the business. IFM also announced that Michael Kulper will

SEATTLE–(BUSINESS WIRE)–Compvide, Inc. kondigt vandaag de commerciële lancering van zijn CIMED-platform aan. De CIMED-AP-, CIMED-LP- en CIMED-CP-kits evalueren respectievelijk de alternatieve, lectine- en klassieke complementroutes, waarbij gebruik wordt gemaakt van 50% serum om tests onder meer fysiologische omstandigheden mogelijk te maken. De commerciële lancering volgt op de deelname van Compvide aan de 20e European Meeting on Complement in Human Disease (EMCHD), die van 1 t/m 5 september

SEATTLE–(BUSINESS WIRE)–Compvide, Inc. a annoncé aujourd’hui la mise sur le marché de sa plateforme CIMED. Les kits CIMED-AP, CIMED-LP et CIMED-CP permettent d’évaluer, respectivement, les voies d’activation du complément (alterne, des lectines et classique), en utilisant du sérum à 50 % pour effectuer les tests dans des conditions plus physiologiques. Cette mise sur le marché fait suite à la participation de Compvide à la 20e édition de l’EMCHD (Conférence européenne sur le système du complé

SEATTLE–(BUSINESS WIRE)–Compvide, Inc. anunció hoy el lanzamiento comercial de su plataforma CIMED. Los kits CIMED-AP, CIMED-LP y CIMED-CP evalúan las vías alternativa, de las lectinas y clásica, respectivamente, con suero al 50 % para respaldar los ensayos bajo condiciones más fisiológicas. El lanzamiento comercial llega tras la participación de Compvide en el 20.º Congreso Europeo de Complemento y Enfermedad Humana (EMCHD), realizado del 1 al 5 de septiembre de 2026 en Cardiff (Gales). A tr

SEATTLE–(BUSINESS WIRE)–Compvide, Inc. gab heute die Markteinführung seiner CIMED-Plattform bekannt. Die Kits CIMED-AP, CIMED-LP und CIMED-CP untersuchen jeweils den alternativen, den Lektin- und den klassischen Komplementweg unter Verwendung von 50-prozentigem Serum, um Tests unter physiologischeren Bedingungen zu ermöglichen. Die Markteinführung folgt auf die Teilnahme von Compvide am 20. European Meeting on Complement in Human Disease (EMCHD), das vom 1. bis 5. September 2026 in Cardiff, W

BOSTON–(BUSINESS WIRE)–Starburst ha annunciato oggi una disponibilità generale limitata di Starburst Torin, un motore di analisi nativo per GPU basato su Trino per Starburst Enterprise. Sviluppato partendo dalla libreria NVIDIA cuDF, Torin accelera i carichi di lavoro SQL con esecuzione nativa per GPU, offrendo prestazioni di interrogazione fino a 7 volte più rapide.1 Grazie all’integrazione del motore esistente CPU, Torin offre alle aziende la flessibilità per eseguire carichi di lavoro sull

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.